Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B4
Source: 0001062993-25-010548
Chunk: 219

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B4
Chunk 219
---
 2024 |
|:------------------------------------------|:--|-------------:|
| Operating lease                           |   |              |
| Operating lease right-of-use assets       | $ |      268,571 |
| Operating lease liabilities - current     |   |      116,323 |
| Operating lease liabilities - non-current |   |      205,945 |

Other information related to leases is presented below:

|                                               |   |   Year Ended 
 December 31, 
         2024 |   |
|:----------------------------------------------|:--|-------------:|:--|
| Lease cost                                    |   |              |   |
| Operating lease cost                          | $ |      123,777 |   |
| Other information                             |   |              |   |
| Operating cash flows used in operating leases |   |      (70,080 | ) |
| Remaining lease term (in years)               |   |         2.42 |   |
| Discount rate                                 |   |          10% |   |

As of December 31, 2024, the annual future minimum lease payments of the Company's operating lease liabilities were as follows:

| Year ending December 31,                          
 2025                                              |   | 142,262 |   |
|:--------------------------------------------------|:--|--------:|:--|
| 2026                                              |   | 146,530 |   |
| 2027                                              |   |  74,348 |   |
| Total future minimum lease payments, undiscounted |   | 363,140 |   |
| Present value discount                            |   | (40,872 | ) |
| Total lease liability                             | $ | 322,268 |   |

F-16 Medicus Pharma Ltd.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2024 and 2023
[expressed in United States dollars, except share amounts]

6. Share capital

Authorized The Company has authorized an unlimited number of common shares participating, voting and without par value. Each holder of common shares is entitled to one vote for each share owned on all matters voted upon by shareholders. Conversion of preferred shares Prior to the RTO, the Company had 13,491,174 of Series A and Series A-1 preferred shares issued and outstanding with no par value. The preferred shares were convertible at any time at the option of the holder into common shares at the series conversion rate unless there is a recapitalization event, in